Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Cole, JH; Raffel, J; Friede, T; Eshaghi, A; Brownlee, WJ; Chard, D; De Stefano, N; Enzinger, C; Pirpamer, L; Filippi, M; Gasperini, C; Rocca, MA; Rovira, A; Ruggieri, S; Sastre-Garriga, J; Stromillo, ML; Uitdehaag, B; Vrenken, H; Barkhof, F; Nicholas, R; Ciccarelli, O; MAGNIMS study group.
Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
Ann Neurol. 2020;
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Enzinger Christian
Pirpamer Lukas

Dimensions Citations:

Plum Analytics:
During the natural course of MS, the brain is exposed to ageing as well as disease effects. Brain ageing can be modelled statistically; the so-called 'brain-age' paradigm. Here, we evaluated whether brain-predicted age difference (brain-PAD) was sensitive to the presence of MS, clinical progression and future outcomes. In a longitudinal, multi-centre sample of 3,565 MRI scans, in 1,204 MS and clinically-isolated syndrome (CIS) patients and 150 healthy controls (mean follow-up time: patients 3.41 years, healthy controls 1.97 years), we measured 'brain-predicted age' using T1-weighted MRI. We compared brain-PAD between MS and CIS patients and healthy controls, and between disease subtypes. Relationships between brain-PAD and Expanded Disability Status Scale (EDSS) were explored. MS patients had markedly higher brain-PAD than healthy controls (mean brain-PAD +10.3 years [95% CI 8.5, 12.1] versus 4.3 years [-2.1, 6.4], p < 0.001). The highest brain-PADs were in secondary-progressive MS (+19.4 years [17.1, 21.9]). Brain-PAD at study entry predicted time-to-disability progression (hazard ratio 1.02 [1.01, 1.03], p < 0.001); though normalised brain volume was a stronger predictor. Greater annualised brain-PAD increases were associated with greater annualised EDSS score (r = 0.26, p < 0.001). The brain-age paradigm is sensitive to MS-related atrophy and clinical progression. A higher brain-PAD at baseline was associated with more rapid disability progression and the rate of change in brain-PAD related to worsening disability. Potentially, 'brain-age' could be used as a prognostic biomarker in early-stage MS, to track disease progression or stratify patients for clinical trial enrolment. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

© Med Uni Graz Impressum